Collaboration, License and Purchase Agreements - Narrative (Details 2) (USD $)	12 Months Ended			0 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 03, 2013	Jun. 27, 2013 quarter	Sep. 12, 2014	Oct. 31, 2013	May 31, 2012	Aug. 30, 2011	Nov. 30, 2007	Aug. 31, 2012 payment	Jul. 31, 2009	Dec. 31, 2013	Feb. 28, 2010	Aug. 31, 2006	Jul. 31, 2014	Jul. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Service and other revenue	$ 3,424,000	$ 1,313,000	$ 38,000
Contract revenue	0	0	8,462,000
Sumavel DosePro [Member] | Royalty Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amortization of Intangible Assets	591,000	1,242,000	1,353,000
Altus Formulation Inc. Development and Option Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable up front fee payment				750,000
Total future milestone payments	3,500,000
Agreement termination notice period	30 days
Valeant Pharmaceuticals North America LLC Co-Promotions Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination notice period					6 months
Agreement Term, Extension Period					12 months
Product Sample Resupply Agreement, Period					6 months
Agreement Term, Tail Payment Due Upon Completion, Period					6 months
Agreement termination notice based on performance measurements					30 days
Agreement termination notice based on performance measurements, number of quarters					1
Agreement termination notice based on change in control of ownership					90 days
Service and other revenue	3,357,000	1,109,000
Durect Development and License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Minimum future milestone payments			103,000,000
Royalty agreement term			15 years
Durect Development and License Agreement [Member] | Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Annual external development expense obligation			1,000,000
Durect Development and License Agreement [Member] | Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable up-front payment			2,250,000
Daravita License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination notice period						12 months
Milestone payments made							2,750,000	1,000,000	750,000
Royalty agreement term						15 years
Automatic extension of arrangement term						3 years
Daravita License Agreement [Member] | Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable up-front payment										500,000
Astellas Pharma Us Inc Co Promotion Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non-refundable up-front payment												2,000,000
Milestone payments received												18,000,000
Deferred agreement payments												20,000,000
Contract revenue			8,462,000
Annual tail payment liability											742,000					1,218,000	2,032,000
Interest expense	87,000	368,000
Service fee reduction											1,500,000
Number of annual tail payments											2
Present value of the service fee receivable and tail payment		1,924,000	1,924,000										1,924,000
Recognized shared marketing expense			253,000
Incurred service fee expenses			1,756,000
Astellas Pharma Us Inc Co Promotion Agreement [Member] | Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Service fee rate (percent)												45.00%
Astellas Pharma Us Inc Co Promotion Agreement [Member] | Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Service fee rate (percent)												55.00%
Aradigm Corporation Asset Purchase Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment to acquire tangible and intangible assets															4,000,000
Milestone payment to acquire tangible and intangible assets														4,000,000
Expected amortization expense, 2015	286,000
Expected amortization expense, 2016	286,000
Expected amortization expense, 2017	286,000
Expected amortization expense, 2018	286,000
Expected amortization expense, 2019	286,000
Expected amortization expense, thereafter	$ 1,143,000
Royalty rate	3.00%												3.00%